OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial – ICYMI [Video]

OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company’s Phase 2 clinical trial for OK-101, an investigational therapy targeting neuropathic corneal pain (NCP).

Jacob highlighted a significant milestone for the trial: the first patient dosed. The CEO also noted that OK-101 has previously shown promising results in safety and efficacy during earlier trials for dry eye disease.

Proactive: You’ve got some news out about your Phase 2 trial for OK-101. Why don’t we start there? Let’s remind everyone a little bit about this particular drug and what it’s designed to potentially do.

Gary Jacob: Well, we’re very excited about our program on OK-101, which has already been through a major clinical trial in patient trials. We have a lot of safety data on this drug, and statistical significance as well. In a prior trial for dry eye disease patients, we saw a benefit in treating an ocular pain indication. What’s exciting is that this …